Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Genomic alterations are established, but gene expression profiles are underutilized for refining cancer therapies.
• Acute myeloid leukemia (AML) treatment relies on standard drugs, but resistance remains a challenge.

Purpose of the Study:

• To analyze transcriptional changes in AML cells in response to cytarabine and daunorubicin.
• To identify treatment-relevant genes and pathways associated with drug sensitivity and resistance.
• To explore the therapeutic potential of targeting identified gene expression changes.

Main Methods:

• RNA sequencing was used to analyze transcriptional changes in AML cell lines treated with cytarabine and daunorubicin.
• Comparative analysis of gene expression profiles in treatment-sensitive versus resistant cells.
• Pharmacological validation using EGFR and MEK inhibitors in AML cell lines and a primary AML sample.

Main Results:

• Transcriptional changes were highly cell- and treatment-specific.
• Enriched genes were linked to drug response pathways like calcium ion-dependent exocytosis and chromatin remodeling.
• EGFR and MEK inhibitors synergized with daunorubicin, enhancing treatment response with minimal cytotoxicity.
• This synergistic effect was confirmed in diverse cancer cell lines using public data.

Conclusions:

• Treatment-evoked gene expression changes can guide the development of rational drug combinations.
• This approach shows promise for improving acute myeloid leukemia therapy, particularly for older patients.
• Targeting specific transcriptional pathways offers a novel strategy to overcome drug resistance in AML.